Related Experiment Video
Updated: Nov 11, 2025
08:48
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
3.1K
Associating SARS-CoV-2 Serological Assays with Protection: Where the Field Stands
Mei San Tang1, Christopher W Farnsworth1
1Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO.
Clinical Chemistry
|March 27, 2021
Abstract
No abstract available in PubMed .
Keywords:
55 serological assays have received EUA. NonethelessCOVID-19SARS-CoV-2The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 was met with a rapid introduction of commercially available serological assays for SARS-CoV-2 antibody detection. Soon after being declared an emergency in the USas laboratories gained access to this unprecedented number of assaysexceeding the number of assays available for any other infectious disease and most other laboratory analytes. As a result of this rapid expansion and at times dubious qualityhundreds of serological assays for SARS-CoV-2 were introducedserologythe Food and Drug Administration (FDA) began reviewing and regulating all SARS-CoV-2 serological assays under emergency use authorization (EUA). To datethe utility of SARS-CoV-2 serological testing remained unclear
